{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:17:57Z","timestamp":1778102277765,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune related adverse events impacting the liver are common from immune checkpoint inhibitor (ICI) therapy; however, there is little data regarding the subclinical impact of ICIs on liver inflammation. The study aims to determine whether ICI therapy affects liver attenuation and liver enzymes in melanoma patients with and without hepatic steatosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, cohort study was conducted of patients with advanced melanoma treated with ICI therapy who received serial PET-CT scans at the Vanderbilt University Medical Center (VUMC). Primary outcomes included: liver attenuation measured by PET-CT\/non-contrast CT and liver enzymes. Hepatic steatosis was diagnosed by radiologists on clinical imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 839 patients with advanced melanoma treated with ICIs, 81 had serial PET-CT scans approximately 12\u00a0months apart and long-term survival; of these 11 patients had pre-existing steatosis\/steatohepatitis. Overall, ICI was not associated with significant increases in liver enzymes in all patients; modest decreases in liver enzymes were observed in patients with pre-existing steatosis\/steatohepatitis. Similarly, liver attenuation did not change from baseline to post-treatment (58.44 vs 60.60 HU,\u2009+\u20092.17, <jats:italic>p<\/jats:italic>\u2009=\u20090.055).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ICIs may not chronically affect liver enzymes or liver attenuation, a non-invasive measure of liver fat content and inflammation, in the general population or in those with pre-existing steatosis\/steatohepatitis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10090-9","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T10:13:38Z","timestamp":1663668818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint inhibitors and their impact on liver enzymes and attenuation"],"prefix":"10.1186","volume":"22","author":[{"given":"Benjamin C.","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron X. T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik","family":"Turker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"issue":"6","key":"10090_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/J.JHEP.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181\u201390. https:\/\/doi.org\/10.1016\/J.JHEP.2018.01.033.","journal-title":"J Hepatol"},{"issue":"1","key":"10090_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/HEP.31227","volume":"72","author":"T Peeraphatdit","year":"2020","unstructured":"Peeraphatdit T, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315\u201329. https:\/\/doi.org\/10.1002\/HEP.31227.","journal-title":"Hepatology"},{"key":"10090_CR3","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother cancer. 2021;9(6). https:\/\/doi.org\/10.1136\/JITC-2021-002435","DOI":"10.1136\/JITC-2021-002435"},{"key":"10090_CR4","doi-asserted-by":"publisher","unstructured":"Patrinely JR, McGuigan B, Chandra S, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021;10(1) https:\/\/doi.org\/10.1080\/2162402X.2021.1875639","DOI":"10.1080\/2162402X.2021.1875639"},{"key":"10090_CR5","doi-asserted-by":"publisher","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022. Published online January 26, 2022:1\u201314 https:\/\/doi.org\/10.1038\/s41571-022-00600-w","DOI":"10.1038\/s41571-022-00600-w"},{"issue":"10","key":"10090_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J Clin Invest. 2007;117(10):2974\u201382. https:\/\/doi.org\/10.1172\/JCI31344.","journal-title":"J Clin Invest"},{"issue":"24","key":"10090_CR7","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299\u2013311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981.","journal-title":"Circulation"},{"key":"10090_CR8","doi-asserted-by":"publisher","unstructured":"Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother cancer. 2021;9(10) https:\/\/doi.org\/10.1136\/JITC-2021-003066","DOI":"10.1136\/JITC-2021-003066"},{"issue":"2","key":"10090_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/ANNONC\/MDW443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(2):368\u201376. https:\/\/doi.org\/10.1093\/ANNONC\/MDW443.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10090_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/JAMAONCOL.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234\u201340. https:\/\/doi.org\/10.1001\/JAMAONCOL.2015.4368.","journal-title":"JAMA Oncol"},{"issue":"1","key":"10090_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/HEP.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/HEP.28431.","journal-title":"Hepatology"},{"issue":"17","key":"10090_CR12","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMOA2029349\/SUPPL_FILE\/NEJMOA2029349_DATA-SHARING.PDF","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559\u201369. https:\/\/doi.org\/10.1056\/NEJMOA2029349\/SUPPL_FILE\/NEJMOA2029349_DATA-SHARING.PDF.","journal-title":"N Engl J Med"},{"key":"10090_CR13","doi-asserted-by":"publisher","unstructured":"Strauss L, Mahmoud MAA, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43) https:\/\/doi.org\/10.1126\/SCIIMMUNOL.AAY1863","DOI":"10.1126\/SCIIMMUNOL.AAY1863"},{"issue":"6","key":"10090_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1148\/RG.296095513\/ASSET\/IMAGES\/LARGE\/G09OC23G09X.JPEG","volume":"29","author":"DT Bol","year":"2009","unstructured":"Bol DT, Merkle EM. Diffuse liver disease: Strategies for hepatic CT and MR imaging. Radiographics. 2009;29(6):1591\u2013614. https:\/\/doi.org\/10.1148\/RG.296095513\/ASSET\/IMAGES\/LARGE\/G09OC23G09X.JPEG.","journal-title":"Radiographics"},{"key":"10090_CR15","doi-asserted-by":"publisher","unstructured":"Barrett JF, Keat N. Artifacts in CT: Recognition and avoidance. Radiographics. 2004;24(6) https:\/\/doi.org\/10.1148\/RG.246045065\/ASSET\/IMAGES\/LARGE\/G04NV25G30X.JPEG","DOI":"10.1148\/RG.246045065\/ASSET\/IMAGES\/LARGE\/G04NV25G30X.JPEG"},{"issue":"10","key":"10090_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2021-003066","volume":"9","author":"BR Halle","year":"2021","unstructured":"Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer. 2021;9(10): e003066. https:\/\/doi.org\/10.1136\/JITC-2021-003066.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"10090_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/ANNRHEUMDIS-2018-EULAR.5840","volume":"77","author":"A Tison","year":"2018","unstructured":"Tison A, Quere G, Misery L, et al. OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. Ann Rheum Dis. 2018;77(Suppl 2):147\u2013147. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2018-EULAR.5840.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10090_CR18","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/JGH.14889","volume":"35","author":"K Sawada","year":"2020","unstructured":"Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J Gastroenterol Hepatol. 2020;35(6):1042\u20138. https:\/\/doi.org\/10.1111\/JGH.14889.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10090_CR19","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1136\/JITC-2021-002916","volume":"9","author":"K Poels","year":"2021","unstructured":"Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. J Immunother Cancer. 2021;9(6):2916. https:\/\/doi.org\/10.1136\/JITC-2021-002916.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10090_CR20","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299\u2013311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981.","journal-title":"Circulation"},{"key":"10090_CR21","doi-asserted-by":"publisher","unstructured":"Wu B, Chiang HC, Sun X, et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother cancer. 2020;8(2) https:\/\/doi.org\/10.1136\/JITC-2020-000964","DOI":"10.1136\/JITC-2020-000964"},{"key":"10090_CR22","doi-asserted-by":"publisher","unstructured":"Pingili AK, Chaib M, Sipe LM, et al. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep. 2021;35(12) https:\/\/doi.org\/10.1016\/J.CELREP.2021.109285","DOI":"10.1016\/J.CELREP.2021.109285"},{"issue":"2","key":"10090_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14728222.2021.1869213","volume":"25","author":"JE Kim","year":"2021","unstructured":"Kim JE, Patel K, Jackson CM. The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert Opin Ther Targets. 2021;25(2):101\u201313. https:\/\/doi.org\/10.1080\/14728222.2021.1869213.","journal-title":"Expert Opin Ther Targets"},{"issue":"21","key":"10090_CR24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMOA1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 2015;372(21):2006. https:\/\/doi.org\/10.1056\/NEJMOA1414428.","journal-title":"N Engl J Med"},{"key":"10090_CR25","doi-asserted-by":"publisher","unstructured":"Qiu Y, Chen T, Hu R, et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res 2021 91. 2021;9(1):1\u201319 https:\/\/doi.org\/10.1186\/S40364-021-00327-3","DOI":"10.1186\/S40364-021-00327-3"},{"key":"10090_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.06.001","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Cell Metabolism Review Macrophages and Metabolism in the Tumor Microenvironment. Published online. 2019. https:\/\/doi.org\/10.1016\/j.cmet.2019.06.001.","journal-title":"Published online"},{"issue":"5","key":"10090_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMBIO.2020.152009","volume":"225","author":"D Mihic-Probst","year":"2020","unstructured":"Mihic-Probst D, Reinehr M, Dettwiler S, et al. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. Immunobiology. 2020;225(5): 152009. https:\/\/doi.org\/10.1016\/J.IMBIO.2020.152009.","journal-title":"Immunobiology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10090-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T10:15:10Z","timestamp":1663668910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10090"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10090-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Vanderbilt University institutional review board. All methods were carried out in accordance with relevant guidelines and regulations or declaration of helsinki. Written informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"998"}}